Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.
Cyclic lipodepsipeptide compounds of the echinocandin class exhibit broad-spectrum antifungal activity and have been shown to be effective in the treatment of Pneumocystis carinii pneumonia in laboratory animal models. Previous studies have led investigators to propose that these compounds, active against fungal cell walls, are selectively active against the cyst forms of P. carinii. We demonstrate that a semisynthetic, water-soluble echinocandin analog, LY307853, is effective in reducing the number of all life cycle forms of P. carinii and is more effective in mice immunosuppressed with monoclonal antibody to L3T4+ cells than in mice immunosuppressed with dexamethasone. Treatment of P. carinii isolates with LY307853 in a short-term in vitro culture model resulted in cytoarchitectural alterations suggesting that this echinocandin may interfere with the export of surface glycoprotein and the formation of the tubular elements normally found on the surfaces of trophic forms. The cytoarchitectural changes in trophic forms treated in vitro with LY307853 were also observed in trophic forms in the lung tissue of rats treated with a closely related echinocandin analog, LY303366.
Bartlett
M S
MS
Department of Pathology, Indiana University School of Medicine, Indianapolis 46202-5120, USA. mbartlet@indyvax.iupui.edu
Current
W L
WL
Goheen
M P
MP
Boylan
C J
CJ
Lee
C H
CH
Shaw
M M
MM
Queener
S F
SF
Smith
J W
JW
D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D002473:Cell Wall / Q000187:drug effects / Q000648:ultrastructure; D003907:Dexamethasone; D054714:Echinocandins; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents; D008168:Lung / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D008854:Microscopy, Electron; D010456:Peptides, Cyclic / Q000494:pharmacology* / Q000627:therapeutic use; D011010:Pneumocystis / Q000187:drug effects* / Q000648:ultrastructure; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000382:microbiology; D051381:Rats
D000935:Antifungal Agents; D054714:Echinocandins; D007166:Immunosuppressive Agents; C102785:LY 307853; D010456:Peptides, Cyclic; D003907:Dexamethasone; D000077612:Anidulafungin